[ad_1] BASEL, Switzerland & SHANGHAI–(BUSINESS WIRE)– Syngenta Group today announced financial results for the first half and the second quarter of 2023. Sales for the first half of 2023 were…
Tag: BioSpace
Cybin to Acquire Small Pharma Inc. | BioSpace
[ad_1] – All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics – – Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and…
Zhongchao Inc. Announces Serving over 10,000 Breast Cancer Patients with Its Comprehensive Disease Management | BioSpace
[ad_1] SHANGHAI, Aug. 24, 2023 /PRNewswire/ — Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a platform-based internet technology company offering services for patients with cancer and other major diseases,…
J&J Cuts R&D at Netherlands Infectious Disease, Vaccine Unit | BioSpace
[ad_1] Pictured: J&J business center in Switzerland/iStock, yuelan Johnson & Johnson appears to be winding down research at its infectious disease and vaccine unit, save for a few select programs, according…
Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program | BioSpace
[ad_1] – Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 – – Company’s intellectual property portfolio now…
RS Oncology presents new drug in early clinical development for Mesothelioma and lung cancer patients | BioSpace
[ad_1] Start-up US biotech company tackling rare diseases presents three case studies in France LILLE, France–(BUSINESS WIRE)– RS Oncology is bringing exciting new science to patients who will have the…
IMAGIO consortium receives Innovative Health Initiative EUR 24 million grant to improve cancer treatments | BioSpace
[ad_1] The Innovative Health Initiative has awarded a EUR 24 million grant to the IMAGIO consortium of clinical partners coordinated by Philips, with additional resources and funding from industry…
XNK Therapeutics Enters into Research Agreement with Global Pharma Company | BioSpace
[ad_1] HUDDINGE, Sweden, May 4, 2023 /PRNewswire/ — XNK Therapeutics AB (“XNK”) today announced that the company’s autologous natural killer (NK) cell therapy candidate XNK04 will be evaluated in combination…
U.S. Food & Drug Administration Issues Complete Response Letter for TransCon™ PTH in Hypoparathyroidism | BioSpace
[ad_1] FDA cited concerns related to the manufacturing control strategy for variability of delivered dose in the TransCon PTH drug/device combination product No new preclinical studies, or Phase…
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023 | BioSpace
[ad_1] Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it…